J Cancer 2018; 9(15):2687-2692. doi:10.7150/jca.25493 This issue Cite

Research Paper

Analysis of Clinical characteristics to predict pathologic complete response for patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy

Haihua Peng1,2*, Chengtao Wang2*, Weiwei Xiao3*, Xiaodan Lin1, Kaiyun You4, Jun Dong2, Zhenyu Wang2, Xiaobi Yu2, Zhifan Zeng3, Tongchong Zhou1, Yuanhong Gao3✉, Bixiu Wen2✉

1. Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou 510075, China
2. Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
3. Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Guangzhou 510060, China
4. Department of Radiation Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
*: these authors contributed equally to this work.

Citation:
Peng H, Wang C, Xiao W, Lin X, You K, Dong J, Wang Z, Yu X, Zeng Z, Zhou T, Gao Y, Wen B. Analysis of Clinical characteristics to predict pathologic complete response for patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. J Cancer 2018; 9(15):2687-2692. doi:10.7150/jca.25493. https://www.jcancer.org/v09p2687.htm
Other styles

File import instruction

Abstract

To explore clinical characteristics which could be applied to predict pathologic complete response (pCR) for patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy (neo-CRT) and total mesorectal excision (TME). 297 patients with locally advanced rectal cancer (cT3-4 or cN+) who were treated with neo-CRT followed by TME were retrospectively reviewed. Clinical characteristics including age, gender, tumor distance from anus, serum CEA, hemoglobin levels before treatment and clinical TN stage were used to investigate the association with pCR after neo-CRT. Seventy-nine (26.6%) patients achieved pCR after neo-CRT. pCR were achieved in 42 (34.4%) patients in cT1-3 stage and 37 (21.1%) in cT4 stage. pCR rate was 36.4% and 16.4% for patients with pre-treatment serum CEA ≤5.33ng/ml and >5.33ng/ml, respectively. Uni- and multi-variate analyses revealed that pre-treatment serum CEA level ≤5.33ng/ml and clinical T stage, (i.e., cT1-3 versus cT4) were highly correlated with pCR (p < 0.05). Clinical T stage and pre-treatment serum CEA level were strongly associated with pCR for patients with locally advanced rectal cancer treated with neo-CRT followed by TME which could be applied as clinical predictors for pCR.

Keywords: Rectal cancer, Neoadjuvant chemoradiotherapy, Total mesorectal excision, TN stage, CEA, Pathologic complete response


Citation styles

APA
Peng, H., Wang, C., Xiao, W., Lin, X., You, K., Dong, J., Wang, Z., Yu, X., Zeng, Z., Zhou, T., Gao, Y., Wen, B. (2018). Analysis of Clinical characteristics to predict pathologic complete response for patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Journal of Cancer, 9(15), 2687-2692. https://doi.org/10.7150/jca.25493.

ACS
Peng, H.; Wang, C.; Xiao, W.; Lin, X.; You, K.; Dong, J.; Wang, Z.; Yu, X.; Zeng, Z.; Zhou, T.; Gao, Y.; Wen, B. Analysis of Clinical characteristics to predict pathologic complete response for patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. J. Cancer 2018, 9 (15), 2687-2692. DOI: 10.7150/jca.25493.

NLM
Peng H, Wang C, Xiao W, Lin X, You K, Dong J, Wang Z, Yu X, Zeng Z, Zhou T, Gao Y, Wen B. Analysis of Clinical characteristics to predict pathologic complete response for patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. J Cancer 2018; 9(15):2687-2692. doi:10.7150/jca.25493. https://www.jcancer.org/v09p2687.htm

CSE
Peng H, Wang C, Xiao W, Lin X, You K, Dong J, Wang Z, Yu X, Zeng Z, Zhou T, Gao Y, Wen B. 2018. Analysis of Clinical characteristics to predict pathologic complete response for patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. J Cancer. 9(15):2687-2692.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image